Erschienen in:
01.10.2009 | Original Article
Gastric Pentadecapeptide BPC 157 and Short Bowel Syndrome in Rats
verfasst von:
Marko Sever, Robert Klicek, Bozo Radic, Luka Brcic, Ivan Zoricic, Domagoj Drmic, Mihovil Ivica, Ivan Barisic, Spomenko Ilic, Lidija Berkopic, Alenka Boban Blagaic, Marijana Coric, Danijela Kolenc, Hrvoje Vrcic, Tomislav Anic, Sven Seiwerth, Predrag Sikiric
Erschienen in:
Digestive Diseases and Sciences
|
Ausgabe 10/2009
Einloggen, um Zugang zu erhalten
Abstract
The gastric pentadecapeptide BPC 157, which was shown to be safe as an antiulcer peptide in trials for inflammatory bowel disease (PL14736, Pliva), successfully healed intestinal anastomosis and fistula in rat. Therefore, we studied for 4 weeks rats with escalating short bowel syndrome and progressive weight loss after small bowel resection from fourth ileal artery cranially of ileocecal valve to 5 cm beneath pylorus. BPC 157 (10 μg/kg or 10 ng/kg) was given perorally, in drinking water (12 ml/rat/day) or intraperitoneally (once daily, first application 30 min following surgery, last 24 h before sacrifice). Postoperatively, features of increasingly exhausted presentation were: weight loss appearing immediately regardless of villus height, twofold increase in crypt depth and fourfold increase in muscle thickness within the first week, jejunal and ileal overdilation, and disturbed jejunum/ileum relation. In contrast, constant weight gain above preoperative values was observed immediately with BPC 157 therapy, both perorally and parenterally, and villus height, crypt depth, and muscle thickness [inner (circular) muscular layer] also increased, at 7, 14, 21, and 28 days. Moreover, rats treated with pentadecapeptide BPC 157 showed not different jejunal and ileal diameters, constant jejunum-to-ileum ratio, and increased anastomosis breaking strength. In conclusion, pentadecapeptide BPC 157 could be helpful to cure short bowel syndrome.